ClinicalTrials.Veeva

Menu
A

Ankara City Hospital | Children's Hospital - Pedriatic Nephrology Department

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Atezolizumab
Pembrolizumab
Trastuzumab
Pertuzumab
Abemaciclib
Tiragolumab
Ifinatamab
Giredestrant
Azacitidine
Topotecan

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

40 of 147 total trials

A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (VIVID-2)

The reason for this study is to determine the long-term efficacy and safety of the study drug mirikizumab in participants with Crohn's disease.

Active, not recruiting
Crohn's Disease
Drug: Mirikizumab

This study will evaluate the safety of tobemstomig alone or in combination with tiragolumab compared with atezolizumab in participants with previousl...

Active, not recruiting
Urothelial Cancer
Drug: Tiragolumab
Drug: Atezolizumab

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with end...

Enrolling
Early Breast Cancer
Drug: Endocrine Therapy of Physician's Choice
Drug: Abemaciclib

This Phase II, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant compared with physician's choice of en...

Active, not recruiting
Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
Drug: Fulvestrant or an Aromatase Inhibitor (Physician Choice)
Drug: LHRH Agonist

This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letr...

Enrolling
Breast Cancer
Drug: Placebo
Drug: Letrozole

The purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse....

Active, not recruiting
Cytochrome P-450
Antineoplastic Agents, Hormonal
Drug: Placebo for Abemaciclib
Drug: Abiraterone

This is a global Phase III, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of adjuvant treatment wit...

Active, not recruiting
Muscle-invasive Bladder Cancer
Device: Signatera
Other: Placebo

The purpose of this study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo in participants with unresect...

Active, not recruiting
Esophageal Squamous Cell Carcinoma
Drug: Atezolizumab
Drug: Atezolizumab Matching Placebo

The purpose of this study is to assess if adding LY3537982 in combination with standard of care anti-cancer drugs is more effective than standard of...

Enrolling
Carcinoma, Non-Small-Cell Lung
Neoplasm Metastasis
Drug: Carboplatin
Drug: Pemetrexed

This study was designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lun...

Enrolling
Small Cell Lung Cancer
Drug: Topotecan
Drug: Amrubicin

The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cance...

Enrolling
Breast Neoplasms
Drug: Anastrozole
Drug: Tamoxifen

The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy, and how well imlunestrant with abemaci...

Active, not recruiting
Neoplasm Metastasis
Breast Neoplasms
Drug: Imlunestrant
Drug: Abemaciclib

The purpose of this study is to evaluate the efficacy and safety of ociperlimab + tislelizumab compared with that of pembrolizumab in adults with PD-...

Active, not recruiting
Non-small Cell Lung Cancer
NSCLC
Drug: Placebo
Drug: Tislelizumab

This study will be conducted in two parts. Part 1 will be the Dose Confirmation portion to determine recommended Phase 3 dose (RPTD) of venetoclax in...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Drug: Venetoclax
Drug: Azacitidine

The reason for this study is to see if the study drug, selpercatinib, compared to placebo is effective and safe in delaying cancer return in particip...

Active, not recruiting
Carcinoma, Non-Small-Cell Lung
Drug: Placebo
Drug: Selpercatinib

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of tobemstomig (RO7247669) in combination with platinum-based che...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Pembrolizumab
Drug: Paclitaxel

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor,...

Enrolling
Non Small Cell Lung Cancer
Drug: Docetaxel
Biological: Telisotuzumab Vedotin

This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, b...

Enrolling
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Diagnostic Test: FoundationOne Liquid CDx Assay (F1LCDx)
Drug: Giredestrant

This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced Cutaneous S...

Active, not recruiting
Cutaneous Squamous Cell Carcinoma
Drug: INCB099280

This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced solid tumor...

Active, not recruiting
Advanced Solid Tumor
Drug: INCB099280

Trial sponsors

A
Roche logo
Lilly logo
AbbVie logo
A
BioNTech logo
Incyte logo
T
Daiichi Sankyo logo
A

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems